Charles River's Endotoxin Testing Automation Cuts Scrap 2%, Lifts Labor 87%

Charles River Laboratories reached full operational capacity on its automated cartridge manufacturing suite for Endosafe endotoxin testing in the third quarter, the company announced September 8. The system, which went fully live in July, represents the company's clearest operational bet after a year spent divesting businesses and narrowing focus.

The automation delivers concrete improvements. Scrap rates dropped 2 percent compared to manual production, invalid cartridge rates fell 13 percent, and capacity across Trillium and LAL cartridge lines increased 14 percent. Labor productivity jumped 87 percent, freeing skilled workers from routine inspection tasks. The new system inspects every cartridge for thickness, reagent fill, and seal integrity—replacing spot-check sampling with total coverage and unique ID traceability.

Manufacturing segment shows strength

Those operational gains translated to the Manufacturing segment's non-GAAP operating margin, which climbed to 37.8 percent in the second quarter from 32.8 percent a year earlier. Organic revenue in the segment grew 1.3 percent, driven by the Microbial Solutions business that includes the Endosafe line. The Discovery and Safety Assessment segment posted its highest net book-to-bill ratio in nearly four years, prompting Charles River to raise both revenue and non-GAAP earnings per share guidance for 2026.

Company-wide margins tell a different story

The broader financial picture remains strained. Charles River reported a GAAP loss of $0.03 per share in the second quarter, reversing a $1.06 profit from the prior year, largely due to a $63.7 million loss tied to CDMO and Cell Solutions divestitures. Total revenue declined 2.7 percent year-over-year to $1.00 billion. Organic revenue growth of 0.1 percent marked the strongest reading since Q3 2023, though from a low baseline.

Non-GAAP operating margin contracted to 20.5 percent from 22.1 percent, and non-GAAP earnings per share fell 3.2 percent to $3.02. The Discovery and Safety Assessment segment saw its non-GAAP margin decline to 25.6 percent from 27.4 percent despite improved study volume, indicating that increased work has not yet converted to proportional profit. Research Models and Services revenue dropped 1.8 percent, with margins slipping to 24.5 percent from 25.3 percent as demand for small research models in North America continues to weaken.

Why it matters

Charles River's automation success demonstrates that targeted manufacturing improvements can deliver measurable efficiency gains in contract research operations. But the company faces a critical test: whether operational excellence in one product line can offset margin compression across larger business segments. The divergence between Manufacturing's expanding margins and DSA's contracting profitability suggests the automation playbook needs to scale beyond endotoxin testing to move the company's overall financial trajectory.

Hedge fund ownership increased from 43 to 47 funds in the most recent quarter, while short interest stands at 6.14 percent of float. The stock trades at a forward price-to-earnings ratio of 22.47 as of September 21, a multiple that assumes margin pressure in DSA and Research Models will ease.

These details were first reported by Insider Monkey.